Hutchmed (HCM) said late Thursday it will receive a $10 million milestone payment through its partner Takeda (TAK) following a national reimbursement recommendation in Spain for Fruzaqla as a treatment for patients with metastatic colorectal cancer.
Hutchmed said the recommendation was the first in Europe for the drug, also called fruquintinib.
Takeda retains the exclusive license to develop, commercialize and manufacture Fruzaqla outside mainland China, Hong Kong and Macau.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments